We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists. Read More
Ten of the nation’s highest-ranked hospitals charge health insurance companies and patients paying out of pocket far more than the amount Medicare pays for several infused drugs, according to a report published in the Nov. 8 issue of the Journal of the American Medical Association (JAMA) Internal Medicine. Read More
A single dose of Regeneron’s COVID-19 antibody cocktail, REGEN-COV, slashed the risk of contracting the coronavirus by 81.6 percent up to eight months after treatment in a phase 3 trial. Read More
Two U.S. subsidiaries of Indian generics company Sun Pharmaceutical Industries have reached settlements totaling $85 million with plaintiffs in the companies’ drug-pricing antitrust litigation, said Sun in a statement. Read More
Can the federal government force drugmakers to participate in the controversial 340B drug discount program, punishing them with fines if they don’t? Read More
Since 2016, the number of businesses and clinics selling stem cell therapies has quintupled, says a University of California at Irvine professor. Read More
Emergent BioSolutions said, “These are mutually agreed-upon terminations for convenience and neither party is alleging breach of default by the other.” Read More
Following a year in which vaccine manufacturing plant Emergent BioSolutions spent many months in the headlines for botching 75 million Johnson & Johnson (J&J) COVID-19 vaccines, the federal government and the troubled company have parted ways. Read More